ChemicalBook > CAS DataBase List > VRT752271

VRT752271

Product Name
VRT752271
CAS No.
869886-67-9
Chemical Name
VRT752271
Synonyms
CS-725;VRT752271;BVD-523FB;Padsevonil;Ulixertinib;VRT752271 HCl;BVD-523 ( VRT752271);Ulixertinib (BVD-523);Ulixertinib, VRT752271;VRT-752271(Ulixertinib)
CBNumber
CB02630104
Molecular Formula
C21H22Cl2N4O2
Formula Weight
433.33
MOL File
869886-67-9.mol
More
Less

VRT752271 Property

Boiling point:
682.8±55.0 °C(Predicted)
Density 
1.359
storage temp. 
Store at -20°C
solubility 
DMSO:93.0(Max Conc. mg/mL);214.62(Max Conc. mM)
Ethanol:43.0(Max Conc. mg/mL);99.23(Max Conc. mM)
pka
13.34±0.50(Predicted)
form 
Powder
color 
White to off-white
InChIKey
KSERXGMCDHOLSS-LJQANCHMSA-N
SMILES
N1C=C(C2C(Cl)=CN=C(NC(C)C)C=2)C=C1C(N[C@@H](C1=CC=CC(Cl)=C1)CO)=O
More
Less

Safety

HS Code 
2933998090
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

ChemScene
Product number
CS-2115
Product name
Ulixertinib
Purity
99.92%
Packaging
5mg
Price
$70
Updated
2021/12/16
Biosynth Carbosynth
Product number
FU157994
Product name
Ulixertinib
Packaging
10mg
Price
$75
Updated
2021/12/16
ChemScene
Product number
CS-2115
Product name
Ulixertinib
Purity
99.92%
Packaging
10mg
Price
$110
Updated
2021/12/16
Biosynth Carbosynth
Product number
FU157994
Product name
Ulixertinib
Packaging
25mg
Price
$125
Updated
2021/12/16
Biosynth Carbosynth
Product number
FU157994
Product name
Ulixertinib
Packaging
50mg
Price
$212.5
Updated
2021/12/16
More
Less

VRT752271 Chemical Properties,Usage,Production

Uses

Ulixertinib is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Inhibits cell proliferation. Anti-cancer.

Synthesis

663611-73-2

869886-90-8

869886-67-9

In step 4, a dry and clean 50 L reaction flask was first purged with nitrogen for 20 min to ensure an oxygen-free environment. Subsequently, DMF (30.20 kg) was added to the reactor and stirring was initiated. The reaction temperature was maintained in the range of 15-25 °C and ASYM-112394 (2.76 kg corrected) was slowly added until the solid was completely dissolved. Next, the reaction mixture was cooled to -10 to -20 °C and 1-hydroxybenzotriazole hydrate (2.10 kg) was added at this temperature. Then, EDCI (2.41 kg) was added in five portions at intervals of about 5-10 minutes. The mixture was further cooled to -20 to -30 °C and ASYM-111888 (1.96 kg) was added. Subsequently, DIEA (1.77kg) was added dropwise at a rate of 3-4kg/h. After completion of the addition, the temperature was increased to 15-25°C at a rate of 5-10°C/h and the reaction was maintained at this temperature. During the reaction, samples were taken at 6-8 h intervals and the level of ASYM-112394 was monitored by HPLC until it dropped below 2%. Upon completion of the reaction, the mixture was cooled to 0-10 °C and quenched with a mixture of ethyl acetate (28.80 kg) and water (12.80 kg) pre-cooled to 0-10 °C. Subsequently, the organic phase was separated by extracting with ethyl acetate (28.80 kg) three times, stirring for 20-30 minutes for each extraction and standing for 20-30 minutes. The organic phases were combined and washed twice with purified water (12.80 kg), stirred for 20-30 minutes each time and left to separate. Afterwards, the organic phase was filtered through an in-line fluid filter and the filtrate was transferred to a 300 L glass-lined reactor. The organic phase was washed twice with 5% acetic acid solution (prepared from acetic acid 2.24 kg and water 42.50 kg) at an addition rate of 10-20 kg/h. Next, the organic phase was washed twice with sodium carbonate solution (prepared from sodium carbonate 9.41 kg and water 48.00 kg), and twice with sodium chloride solution (prepared from sodium chloride 16.00 kg and water 44.80 kg). The washed organic phase was transferred to a 300 L glass-lined reactor, anhydrous sodium sulfate (9.70 kg) was added, and stirred at 15-30 °C for 2-4 hours. The mixture was filtered and the filter cake was treated with silica gel (7.50 kg) preloaded with nutche filter and washed with ethyl acetate (14.40 kg). The filtrates were combined and transferred to a 72 L flask through an in-line fluid filter and concentrated under reduced pressure (pressure -0.08 MPa) at 40 °C to a remaining 3-4 L. MTBE (4.78 kg) was added and crystallized by cooling and stirring to 0-10 °C. Samples were taken after 1 h. The percentage by weight of the mother liquor was monitored by gravimetric analysis until it reached 5% or varied by no more than 1% between successive samples. Finally, the product was collected by vacuum filtration and the filter cake was dried under nitrogen protection at 30-40°C to KF ≤ 0.5%, yielding 3.55 kg of off-white solid product with 100% purity. The product was analyzed by XRPD to confirm the structure, and the specific peak positions and intensities are shown in Tables 2 and 3 of the original article.

in vivo

In the pharmacokinetic study, the sensitivity and specificity of the assay are found to be sufficient for accurately characterizing the plasma pharmacokinetics of Ulixertinib (VRT752271) in Balb/C mice[2].

IC 50

ERK2: 0.3 nM (IC50, at KM ATP (60 μM)); ERK1

References

[1] Patent: WO2016/123574, 2016, A1. Location in patent: Paragraph 0233; 0234; 0235; 0236
[2] Patent: WO2016/123581, 2016, A1. Location in patent: Paragraph 146; 0151; 0152; 0153; 0154
[3] Patent: WO2005/113541, 2005, A1. Location in patent: Paragraph 0089

VRT752271 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

VRT752271 Suppliers

Shanghai Taibao Pharmaceutical Technology Co., Ltd.
Tel
13816752554
Email
1745533547@qq.com
Country
China
ProdList
129
Advantage
58
Kaixin Chemical (Hong Kong) Limited
Tel
010-88886666-01 13112345678
Fax
CDXH21@126.com
Email
loyson@tcypharm.com
Country
China
ProdList
597
Advantage
55
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6003
Advantage
61
Jia Xing Isenchem Co.,Ltd
Tel
0573-85285100 18627885956
Fax
0573-85285100
Email
isenchem@163.com
Country
China
ProdList
9310
Advantage
66
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
Tel
17702719238 18971495150;
Email
sales@sun-shinechem.com
Country
China
ProdList
1077
Advantage
64
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Fax
+86-25-83453306
Email
info@chemlin.com.cn
Country
China
ProdList
15883
Advantage
64
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202 13764082696
Email
info@hanhongsci.com
Country
China
ProdList
42934
Advantage
64
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4747
Advantage
58
Shanghai Topbiochem Technology Co., Ltd
Tel
021-58170097
Email
info@topbiochem.com
Country
China
ProdList
9510
Advantage
58
More
Less

View Lastest Price from VRT752271 manufacturers

Career Henan Chemical Co
Product
VRT752271 869886-67-9
Price
US $6.68/KG
Min. Order
1KG
Purity
97%-99%
Supply Ability
1kg-1000kg
Release date
2020-01-08

869886-67-9, VRT752271Related Search:


  • 1H-Pyrrole-2-carboxaMide, 4-[5-chloro-2-[(1-Methylethyl)aMino]-4-pyridinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-
  • VRT752271
  • 4-[5-Chloro-2-[(1-methylethyl)amino]-4-pyridinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide
  • Ulixertinib
  • VRT-752271(Ulixertinib)
  • VRT752271 HCl
  • 4-[5-Chloro-2-[(1-methylethyl)amino]-4-pyridinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide VRT752271
  • Ulixertinib (BVD-523,VRT752271)
  • 4-(5-Chloro-2-isopropylamino-4-pyridinyl)pyrrole-2-carboxylic acid (S)-[1-(3-chlorophenyl)-2-hydroxyethyl]amide HCl
  • Ulixertinib, VRT752271
  • Padsevonil
  • (S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide
  • BVD-523, BVD 523, BVD523, VRT752271, VRT752271, VRT 752271, ULIXERTINIB
  • Ulixertinib (BVD-523)
  • N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1H-pyrrole-2-carboxamide
  • BVD-523 ( VRT752271)
  • CS-725
  • BVD-523; BVD 523; BVD523; ULIXERTINIB; VRT752271; VRT-752271; VRT 752271
  • 4-[5-Chloro-2-[(1-methylethyl)amino]-4-pyridinyl]-N-[(1S)-1-...
  • Ulixertinib 869886-67-9
  • 4-{5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl}-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide
  • Ulixertinib, 10 mM in DMSO
  • BVD-523FB
  • 869886-67-9
  • 69886-67-9
  • C21H22Cl2N4O2
  • C21H22Cl2N4O2ClH